Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more
Market Cap & Net Worth: Hanall Biopharma (009420)
Hanall Biopharma (KO:009420) has a market capitalization of $1.86 Billion (₩2.72 Trillion) as of March 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #6414 globally and #122 in its home market, demonstrating a -3.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hanall Biopharma's stock price ₩53600.00 by its total outstanding shares 50754857 (50.75 Million).
Hanall Biopharma Market Cap History: 2015 to 2026
Hanall Biopharma's market capitalization history from 2015 to 2026. Data shows growth from $455.83 Million to $1.86 Billion (15.32% CAGR).
Hanall Biopharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hanall Biopharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Hanall Biopharma's market cap is 0.01 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $455.83 Million | $80.02 Billion | -$7.08 Billion | 0.01x | N/A |
| 2016 | $455.83 Million | $82.88 Billion | $2.03 Billion | 0.01x | 0.22x |
| 2017 | $845.80 Million | $84.23 Billion | $5.81 Billion | 0.01x | 0.15x |
| 2018 | $1.25 Billion | $91.84 Billion | $3.30 Billion | 0.01x | 0.38x |
| 2019 | $1.26 Billion | $108.45 Billion | $19.17 Billion | 0.01x | 0.07x |
| 2020 | $1.30 Billion | $88.60 Billion | $19.76 Billion | 0.01x | 0.07x |
| 2021 | $729.67 Million | $101.59 Billion | $8.90 Billion | 0.01x | 0.08x |
| 2022 | $617.02 Million | $110.00 Billion | $251.47 Million | 0.01x | 2.45x |
| 2023 | $1.54 Billion | $134.91 Billion | $3.51 Billion | 0.01x | 0.44x |
| 2024 | $1.34 Billion | $138.94 Billion | -$1.80 Billion | 0.01x | N/A |
Competitor Companies of 009420 by Market Capitalization
Companies near Hanall Biopharma in the global market cap rankings as of March 18, 2026.
Key companies related to Hanall Biopharma by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hanall Biopharma Historical Marketcap From 2015 to 2026
Between 2015 and today, Hanall Biopharma's market cap moved from $455.83 Million to $ 1.86 Billion, with a yearly change of 15.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩1.86 Billion | +22.51% |
| 2025 | ₩1.52 Billion | +13.20% |
| 2024 | ₩1.34 Billion | -12.75% |
| 2023 | ₩1.54 Billion | +148.88% |
| 2022 | ₩617.02 Million | -15.44% |
| 2021 | ₩729.67 Million | -43.87% |
| 2020 | ₩1.30 Billion | +3.31% |
| 2019 | ₩1.26 Billion | +0.28% |
| 2018 | ₩1.25 Billion | +48.36% |
| 2017 | ₩845.80 Million | +85.55% |
| 2016 | ₩455.83 Million | 0.00% |
| 2015 | ₩455.83 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Hanall Biopharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.86 Billion USD |
| MoneyControl | $1.86 Billion USD |
| MarketWatch | $1.86 Billion USD |
| marketcap.company | $1.86 Billion USD |
| Reuters | $1.86 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.